ibogaine has been researched along with Colorectal Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Deng, Y; Huang, H; Huang, Y; Li, X; Lu, A; Lu, J; Pu, Y; Ren, Q; Shi, S; Xia, X; Yang, H; Yang, J; You, O; Zhang, C; Zuo, Y | 1 |
1 other study(ies) available for ibogaine and Colorectal Cancer
| Article | Year |
|---|---|
Voacamine is a novel inhibitor of EGFR exerting oncogenic activity against colorectal cancer through the mitochondrial pathway.
Topics: Adenosine Triphosphate; Animals; Apoptosis; bcl-2-Associated X Protein; Biological Products; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; ErbB Receptors; Ibogaine; Mice; Mitochondria; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |